The Sabin Vaccine Institute works to extend the benefits of immunization to all people by enabling vaccine access and uptake. Sabin brings together national government officials, policy makers, immunization specialists, researchers and advocates to supply decision makers with the data and expertise they need to make evidence-based decisions on vaccines. Our work includes a number of diseases, including:
Vaccine introduction, policy and financing are complex issues, and countries must achieve ambitious immunization targets with limited available resources. To make informed decisions for the health of their people, decision makers need accurate, up-to-date information to identify vulnerable populations, assess burden of disease, evaluate vaccine efficacy and cost-effectiveness, and measure the efficiency of immunization programs.
The onset of meningitis can occur suddenly and progress rapidly, with the potential to become fatal within a matter of hours. Survivors can be left with debilitating neurological side effects ranging from speech disorders to mental retardation and paralysis.
Since 2011, Sabin has worked to improve meningococcal disease estimates, focusing on Latin America. Through regional symposia, research and advocacy, Sabin provides a broader base of knowledge on which to build future initiatives, while bringing together key stakeholders to better understand and fight meningococcal disease.
Researchers find high incidence rates and deaths in first-ever analysis of the disease impac